Volume 13 Issue 3, September 2019

As a key component in deal negotiations, a term sheet must be planned carefully and set out optimally for an asset. Lubor Gaal from Locust Walk discusses how licencors can negotiate the best terms for their biopharma assets.

Immuno-oncology continues to be a highly active area for dealmaking as leading companies seek to expand the treatable patient population for checkpoint inhibitors in indications such as non-small-cell lung cancer and achieve initial success in indications such as pancreatic cancer.

Harnessing its antibody discovery platform Symplex, Symphogen has developed a fully integrated approach to discovering and developing next-generation antibody therapeutics.

Through its innovative, bispecific antibody platform ALiCE, Y-Biologics is discovering and developing next-generation immuno-oncology therapeutics.

Helping advance scientific research, diagnostic and therapeutic applications in disease areas including neuroscience, cancer and rare diseases globally, Abcam develop comprehensive solutions [...] with scientific and commercial partners to generate optimized antibodies, other binders and assays.

Clinical-stage biotech company PharmAbcine is advancing its lead antibody candidate olinvacimab through the clinic, alone and in combination, whilst developing a portfolio of clinical candidates that target key molecules implicated in oncology, angiogenesis and immune surveillance.

Berkeley Lights’ innovative, optofluidics-based technology enables real-time, live, non-destructive, and iterative interrogation of thousands of single cells in integrated, end-to-end workflows for applications such as antibody discovery, cell line development, and T cell functional analytics.

Ablexis, LLC, developer of the AlivaMab Mouse and AlivaMab Discovery Services, LLC, offer customized and streamlined solutions for companies and organizations looking to obtain efficacious and derisked therapeutic antibodies.

Polaris Pharmaceuticals is evaluating its lead therapeutic protein—pegargiminase, a novel targeted cancer therapy that depletes circulating arginine—in combination with standard chemotherapies and immuno-oncology drugs in various cancers, including hepatocellular carcinoma and mesothelioma

Over the past two decades, Wallonia has emerged as a global powerhouse in different strategic areas in the health sector.

iX Biopharma is transforming approved drugs such as ketamine into novel therapies using its wafer-based sublingual technology, to develop therapies for pain, depression and more.

Genome & Company is developing a microbiome-based add-on therapy for programmed cell death 1/programmed cell death 1 ligand 1 inhibitors. It is also developing novel targeted immune checkpoint inhibitors, and believes these two approaches could be combined for personalized therapy.

YUMAB’s antibody discovery and development platform integrates superior technologies for the development of fully human antibodies against complex or difficult novel targets to generate advanced immuno-oncology biotherapeutics.

Biotechnology company Eutilex is developing a portfolio of immuno-oncology T cell, chimeric antigen receptor T cell and antibody therapeutics that are now ready for partnering.

With its two-pronged approach, I-Mab Biopharma is developing biological therapeutics indicated for cancer and autoimmune diseases for the Chinese market and for the rest of the world.

Harnessing the potential of γδ T cells, Incysus Therapeutics has developed two immunotherapy programs that are ready to be launched into the clinic.

Agenus is developing next-generation immunotherapeutics from its discovery platforms, providing the company with a deliberate balance between its wholly owned and partnered pipeline of novel therapies specifically designed to expand the benefit of immuno-oncology for patients with cancer.

VCN Biosciences is developing a highly selective, advanced generation of oncolytic adenoviruses.

OncoImmune develops novel immune-modulators targeting innate checkpoint mechanisms involving CD24–Siglec10 signaling as well as potential best-in-class anti-CTLA-4 antibody therapy that can separate its therapeutic effect from toxicity.